Increased plasma glutamate by antipsychotic medication and its relationship to glutaminase 1 and 2 genotypes in schizophrenia - Juntendo University Schizophrenia Projects (JUSP)

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 31, Issue 7, 2007, Pages 1410-1418

  Maeshima, Hitoshi ^a   Ohnuma, Tohru ^a   Sakai, Yoshie ^a   Shibata, Nobuto ^a   Baba, Hajime ^a   Ihara, Hiroshi ^a   Higashi, Maiko ^a   Ohkubo, Taku ^a   Nozawa, Eiko ^a   Abe, Sawako ^a   Ichikawa, Aya ^a   Nakano, Yoshiyuki ^a   Utsumi, Yushi ^a   Suzuki, Toshihito ^a   Arai, Heii ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

Genotype phenotype correlation; Glutamate; Glutaminase; Polymorphism; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BIOLOGICAL MARKER; CHLORPROMAZINE; GLUTAMIC ACID; GLUTAMINASE; GLUTAMINASE 2; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SULTOPRIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME BLOOD LEVEL; FEMALE; GENETIC ASSOCIATION; GENOMICS; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; REMISSION; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; DNA; FEMALE; GENOTYPE; GLUTAMIC ACID; GLUTAMINASE; HAPLOTYPES; HUMANS; ISOENZYMES; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA;

EID: 34548143372     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.06.009     Document Type: Article

References (45)

1. Akbarian S., Sucher N.J., Bradley D., Tafazzoli A., Trinh D., Hetrick W.P., et al. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 16 (1996) 19-30
2. Aledo J.C., Gomez-Fabre P.M., Olalla L., and Marquez J. Identification of two human glutaminase loci and tissue-specific expression of the two related genes. Mamm Genome 11 (2000) 1107-1110
3. Alfredsson G., and Wiesel F.A. Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology 99 (1989) 322-327
4. Alfredsson G., and Wiesel F.A. Relationships between clinical effects and monoamine metabolites and amino acids in sulpiride-treated schizophrenic patients. Psychopharmacology 101 (1990) 324-331
5. Altamura C.A., Mauri M.C., Ferrara A., Moro A.R., D'Andrea G., and Zamberlan F. Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry 150 (1993) 1731-1733
6. Arinami T., Ohtsuki T., Ishiguro H., Ujike H., Tanaka Y., Morita Y., et al. Genomewide high-density SNP linkage analysis of 236 Japanese families supports the existence of schizophrenia susceptibility loci on chromosomes 1p, 14q, and 20p. Am J Hum Genet 77 (2005) 937-944
7. Deakin J.F., Slater P., Simpson M.D., Gilchrist A.C., Skan W.J., Royston M.C., et al. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J Neurochem 52 (1989) 1781-1786
8. Dingemans P.M., Linszen D.H., Lenior M.E., and Smeets R.M. Component structure of the expanded Brief Psychiatric Rating Scale (BPRS-E). Psychopharmacology 122 (1995) 263-267
9. Evins A.E., Amico E.T., Shih V., and Goff D.C. Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics. J Neural Transm 104 (1997) 761-766
10. Fukuzako H. Neurochemical investigation of the schizophrenic brain by in vivo phosphorus magnetic resonance spectroscopy. World J Biol Psychiatry 2 (2001) 70-82
11. Goff D.C., Tsai G., Manoach D.S., Flood J., Darby D.G., and Coyle J.T. d-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 153 (1996) 1628-1630
12. Goff D.C., Hennen J., Lyoo I.K., Tsai G., Wald L.L., Evins A.E., et al. Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biol Psychiatry 51 (2002) 493-497
13. Halberstadt A.L. The phencyclidine-glutamate model of schizophrenia. Clin Neuropharmacol 18 (1995) 237-249
14. Hashimoto K., Fukushima T., Shimizu E., Komatsu N., Watanabe H., Shinoda N., et al. Decreased serum levels of d-serine in patients with schizophrenia: evidence in support of the N-methyl-d-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 60 (2003) 572-576
15. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Silipo G., and Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 56 (1999) 29-36
16. Heresco-Levy U., Ermilov M., Lichtenberg P., Bar G., and Javitt D.C. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry 55 (2004) 165-171
17. Heresco-Levy U., Javitt D.C., Ebstein R., Vass A., Lichtenberg P., Bar G., et al. d-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 57 (2005) 577-585
18. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148 (1991) 1301-1308
19. Javitt D.C., Zylberman I., Zukin S.R., Heresco-Levy U., and Lindenmayer J.P. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151 (1994) 1234-1236
20. Javitt D.C., Silipo G., Cienfuegos A., Shelley A.M., Bark N., Park M., et al. Adjunctive high-dose glycine in the treatment of schizophrenia. Int J Neuropsychopharmacol 4 (2001) 385-391
21. Kawashima R., Ohnuma T., Shibata N., and Arai H. No genetic association between postsynaptic density-95 gene polymorphisms and schizophrenia. Neurosci Lett 400 (2006) 168-171
22. Kornhuber J., Mack-Burkhardt F., Riederer P., Hebenstreit G.F., Reynolds G.P., Andrews H.B., et al. [3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. J Neural Transm 77 (1989) 231-236
23. Lewis C.M., Levinson D.F., Wise L.H., DeLisi L.E., Straub R.E., Hovatta I., et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am J Hum Genet 73 (2003) 34-48
24. Macciardi F., Lucca A., Catalano M., Marino C., Zanardi R., and Smeraldi E. Amino acid patterns in schizophrenia: some new findings. Psychiatry Res 32 (1990) 63-70
25. Mauri M.C., Ferrara A., Boscati L., Bravin S., Zamberlan F., Alecci M., et al. Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology 37 (1998) 124-129
26. Neeman G., Blanaru M., Bloch B., Kremer I., Ermilov M., Javitt D.C., et al. Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type. Am J Psychiatry 162 (2005) 1738-1740
27. Nishikawa T., Takashima M., and Toru M. Increased [3H]kainic acid binding in the prefrontal cortex in schizophrenia. Neurosci Lett 40 (1983) 245-250
28. Ohnuma T., Augood S.J., Arai H., McKenna P.J., and Emson P.C. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Brain Res Mol Brain Res 56 (1998) 207-217
29. Ohnuma T., Kato H., Arai H., Faull R.L., McKenna P.J., and Emson P.C. Gene expression of PSD95 in prefrontal cortex and hippocampus in schizophrenia. Neuroreport 11 (2000) 3133-3137
30. Ohnuma T., Tessler S., Arai H., Faull R.L., McKenna P.J., and Emson P.C. Gene expression of metabotropic glutamate receptor 5 and excitatory amino acid transporter 2 in the schizophrenic hippocampus. Brain Res Mol Brain Res 85 (2000) 24-31
31. Ohnuma T., Kato H., Arai H., McKenna P.J., and Emson P.C. Expression of Fyn, a non-receptor tyrosine kinase in prefrontal cortex from patients with schizophrenia and its correlation with clinical onset. Brain Res Mol Brain Res 112 (2003) 90-94
32. Ohnuma T., Shibata N., Matsubara Y., Sato S., Yamashina M., and Arai H. No genetic association between polymorphisms in the Fyn kinase gene and age of schizophrenic onset. Neurosci Lett 343 (2003) 70-72
33. Ohnuma T., Suzuki T., and Arai H. Hypothesis: minimal changes in neural transmission in schizophrenia: decreased glutamatergic and GABAergic functions in the prefrontal cortex. Prog Neuropsychopharmacol Biol Psychiatry 29 (2005) 889-894
34. Olalla L., Gutierrez A., Campos J.A., Khan Z.U., Alonso F.J., Segura J.A., et al. Nuclear localization of l-type glutaminase in mammalian brain. J Biol Chem 277 (2002) 38939-38944
35. Olney J.W., and Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52 (1995) 998-1007
36. Overall J.E.G.O. The Brief Psychiatry Rating Scale. Psychol Rep 10 (1962) 799-812
37. Sherman A.D., Davidson A.T., Baruah S., Hegwood T.S., and Waziri R. Evidence of glutamatergic deficiency in schizophrenia. Neurosci Lett 121 (1991) 77-80
38. Simpson M.D., Slater P., Royston M.C., and Deakin J.F. Alterations in phencyclidine and sigma binding sites in schizophrenic brains. Effects of disease process and neuroleptic medication. Schizophr Res 6 (1991) 41-48
39. Sumiyoshi T., Anil A.E., Jin D., Jayathilake K., Lee M., and Meltzer H.Y. Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms. Int J Neuropsychopharmacol 7 (2004) 1-8
40. Sumiyoshi T., Jin D., Jayathilake K., Lee M., and Meltzer H.Y. Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia. Int J Neuropsychopharmacol 8 (2005) 451-455
41. Tortorella A., Monteleone P., Fabrazzo M., Viggiano A., De Luca L., and Maj M. Plasma concentrations of amino acids in chronic schizophrenics treated with clozapine. Neuropsychobiology 44 (2001) 167-171
42. Tsai G., Yang P., Chung L.C., Lange N., and Coyle J.T. d-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 44 (1998) 1081-1089
43. Velligan D., Prihoda T., Dennehy E., Biggs M., Shores-Wilson K., Crismon M.L., et al. Brief psychiatric rating scale expanded version: how do new items affect factor structure?. Psychiatry Res 135 (2005) 217-228
44. Waziri R. Glycine therapy of schizophrenia. Biol Psychiatry 23 (1988) 210-211
45. Yamada K., Ohnishi T., Hashimoto K., Ohba H., Iwayama-Shigeno Y., Toyoshima M., et al. Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and d-serine levels. Biol Psychiatry 57 (2005) 1493-1503